ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 2175 • ACR Convergence 2023

    Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study

    Marc Schmalzing1, Charlotte Both2, Ines Brueckmann2, Javier de Toro Santos3, Tom Sheeran4, Herbert Kellner5 and Ayman Askari6, 1University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, 2Sandoz Hexal AG, Rheumatology, Holzkirchen, Germany, 3University Hospital Coruña, Rheumatology, A Coruña, Spain, 4University of Wolverhampton, New Cross Hospital, Wolverhampton, United Kingdom, 5Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, 6Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Rheumatology, Shropshire, United Kingdom

    Background/Purpose: COMPACT is a multi-country, non-interventional study that evaluated the drug persistence, effectiveness, safety and patient-reported outcomes in patients with rheumatoid arthritis (RA), axial spondyloarthritis…
  • Abstract Number: 2511 • ACR Convergence 2023

    Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies

    Christian Ammitzbøll1, Marianne Kragh Thomsen2, Lars Erik Bartels1, Marie-Louise From Hermansen1, Mathias Hänel3, Rasmus Klose-Jensen1, Mads Christian Lamm Larsen1, Cecile Bo Hansen4, Morgan Oliver Lauritsen1, Susan Mikkelsen5, Clara Mistegaard1, Morten Aagaard Nielsen1, Esben Naeser1, Janne Bille Mønster Olesen5, Peter Garred4, Christian Erikstrup5, Ellen-Margrethe Hauge6 and Anne Troldborg6, 1Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, 3Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, 4Clinical Immunology, sect. 7631, Rigshospitalet, Copenhagen, Denmark, 5Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, 6Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Rituximab (RTX) treatment significantly decreases the antibody response to COVID-19 vaccines, raising concerns about its use. However, unlike during the pandemic, most patients initiating…
  • Abstract Number: 0064 • ACR Convergence 2023

    Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

    Vincent ricchiuti1, Michael Nappi2, Kelly Chun2, Ajay Grover1 and Rubio Punzalan2, 1Labcorp, Dublin, OH, 2Labcorp, Calabasas, CA

    Background/Purpose: The discovery and characterization of the dense fine speckled (DFS, ICAP AC-2) nuclear pattern of antinuclear autoantibodies (ANA) detected in HEp-2 cells by indirect…
  • Abstract Number: 0117 • ACR Convergence 2023

    The Patient Journey to a First Diagnosis of Systemic Sclerosis: Temporal Disease Pattern Identification Using Machine Learning and Data Mining Among US and Japanese Patients

    Francesco Del Galdo1, Yahui Tian2, Stefano Di Donato1 and Mario Ehlers2, 1University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by skin and organ fibrosis and vasculopathy. The Very Early Diagnosis of SSc (VEDOSS) project…
  • Abstract Number: 0227 • ACR Convergence 2023

    Associations of DMARDs with Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases: A Prospective Study

    Rathnam Venkat1, Xiaosong Wang2, Naomi Patel3, Yumeko Kawano2, Abigail Schiff2, Emily Kowalski2, Claire Cook3, Kathleen Vanni2, Grace Qian2, Katarina Bade4, Alene Saavedra2, Shruthi Srivatsan3, Zachary Williams3, Zachary Wallace5 and Jeffrey Sparks6, 1Tufts University School of Medicine, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Massachusetts General Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Massachusetts General Hospital, Newton, MA, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Post-acute sequelae of COVID-19 (PASC, or "long COVID") is defined by the CDC as COVID-19 symptoms persisting for ≥28 days after infection. Patients with…
  • Abstract Number: 0455 • ACR Convergence 2023

    Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

    Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA

    Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
  • Abstract Number: 0602 • ACR Convergence 2023

    Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

    Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA

    Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
  • Abstract Number: 0895 • ACR Convergence 2023

    Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus

    Chaim Putterman1, Elise Mike2 and Sayra Garcia1, 1Albert Einstein College of Medicine, Bronx, NY, 2Johns Hopkins, Bronx, NY

    Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
  • Abstract Number: 1059 • ACR Convergence 2023

    Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data

    Anne Bass1, Fenglong Xie2, Alexa Meara3, Deanna Jannat-Khah4 and Jeffrey Curtis2, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2University of Alabama at Birmingham, Birmingham, AL, 3The Ohio State University Wexner Medical Center, Columbus, OH, 4Hospital For Special Surgery, New York, NY

    Background/Purpose: Immune checkpoint inhibitor (ICI) associated inflammatory arthritis (ICI-IA) has been suggested to occur in approximately 3-6% of ICI-treated patients with cancer1 but most studies…
  • Abstract Number: 1207 • ACR Convergence 2023

    Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database

    Zi Ying Li1, Siyi Huang2, senay Gokcebel3 and Anthony Reginato4, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3School of Public Health | Brown University, Providence, RI, 4The Warren Alpert Medical School of Brown University, Providence, RI

    Background/Purpose: Rheumatic diseases such as rheumatoid arthritis (RA) and Systemic lupus erythematosus (SLE) were known for increased prevalence and risk of death from cardiovascular disease…
  • Abstract Number: 1484 • ACR Convergence 2023

    Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature

    Katarzyna Karpinska-Leydier1, Arseni Khorochkov2, Ambar Morales-Rodriguez1, Nur Barlas1, Sait Barlas1, Abraham Bell1, Magdy El-Din3 and Shristi Basnyat4, 1Florida State University - Cape Coral Hospital, Cape Coral, FL, 2Poznan University of Medical Sciences, Poznań, Poland, 3Florida State University/Lee physicians group, Cape Coral, FL, 4Florida State University/Lee physicians group, Fort Myers, FL

    Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). Current investigations implicate microbiome changes in disease pathogenesis, particularly pathobiont expansions of…
  • Abstract Number: 1670 • ACR Convergence 2023

    Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae

    CAMILA CAETANO1, Tamiris Azamor1, Nikki M. Meyer1, Cassandra Calabrese2, Leonard Calabrese2, Nicolas Piuzzi3, M. Elaine Husni2, Suan-Sin Foo1 and Weiqiang Chen1, 1Cleveland Clinic / Infection Biology Program, Global Center for Pathogen Research and Human Health, Lerner Research Institute, Cleveland, OH, 2Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 3Cleveland Clinic / Department of Orthopedic Surgery, Cleveland, OH

    Background/Purpose: Patients with underlying immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a higher susceptibility to severe COVID19…
  • Abstract Number: 1856 • ACR Convergence 2023

    Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

    Kathlyn Camargo Macias1, Ravi Shahu Khal1, Ariail Schmitz2, Kathleen McCabe1, Taylor Kann1, Marilyn Mosquera3 and Ashwini Komarla4, 1University of Central Florida, Orlando, FL, 2University of Central Florida, St. Cloud, FL, 3University of Central Florida, Casselberry, FL, 4ORLANDO VAMC, Orlando, FL

    Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
  • Abstract Number: 1956 • ACR Convergence 2023

    Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis

    Lilian Otalora Rojas1, Karishma Ramsubeik2, Luis Sanchez-Ramos2, Shastri Motilal3, Jasvinder Singh4 and Gurjit S Kaeley5, 1University of Florida, Ponte Vedra Beach, FL, 2University of Florida, Jacksonville, FL, 3The University of the West Indies, St. Augustine, Trinidad and Tobago, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL

    Background/Purpose: Autoimmune myositis involves a spectrum of rare autoimmune disorders characterized by inflammation and damage to skeletal muscles. The management of these challenging conditions often…
  • Abstract Number: 2186 • ACR Convergence 2023

    Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life

    Matt Makara, Janet Church and Katherine Hammitt, Sjögren’s Foundation, Reston, VA

    Background/Purpose: Sjögren's is a serious and systemic autoimmune disease that affects the entire body, including the nervous system. This study aimed to better understand the…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology